{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 49,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a line chart showing HCQN subscale scores over time and a process diagram for the ongoing trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/30",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.37,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Prior evidence in humans (third party study) showing HCQN subscale scores over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55da5108-f66b-4571-a7fc-439c746295cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.37,
        "y": 0.65
      },
      "kind": "diagram",
      "text": "Ongoing Phase 1/2 trial: Stage 1 (Maximum Tolerated Dose) and Stage 2 (Proof of Concept)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4653540c-aa56-46f0-9990-39d951583a52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Note: HCQN = Heroin Craving Questionnaire, PTSD = Post-traumatic stress disorder, OUD = Opioid use disorder, PCB = Placebo, PK = Pharmacokinetics. (1) Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of March 31st, 2022. Refers to ownership in DemeRx IB. DemeRx NB ownership is 6.3%, which does not give effect to option to acquire further shares which may increase the ownership to up to 57.1% (2) Mash et al., “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes” (2018) (3) Noribogaine Intellectual property resides in DemeRx NB",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32643d42-3d52-4cfd-92c9-c54de7a7e265",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.33,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Ownership, Product, Pharmacology, Product Features, Indications, Current Status, Intellectual Property, Highlight",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b82433f3-88e1-40a0-bb54-a4d55da17094",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.37,
        "y": 0.07
      },
      "kind": "title",
      "text": "A single-dose of ibogaine showed potential for sustained reductions in opioid cravings in 75 opioid-dependent patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f01c3706-2c8b-4faa-be2c-ba126f2438db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77c50e7d-0a6e-49a8-bddd-c816a0d56b39",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "e460856c-f300-4ed2-bc86-930c58522574",
      "evidence": "table/data: Ownership, Product, Pharmacology, Product Features, Indications, Current Status, Intellectual Property, Highlight",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "89b4c64e-64c1-43c1-8ed6-a13a09747d71",
      "evidence": "Ongoing Phase 1/2 trial stages",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}